GLUCAGON KIT
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
10-07-2012
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
GLUCAGON (RECOMBINANT DNA ORIGIN)
Inapatikana kutoka:
ELI LILLY CANADA INC
ATC kanuni:
H04AA01
INN (Jina la Kimataifa):
GLUCAGON
Kipimo:
1MG
Dawa fomu:
KIT
Tungo:
GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG
Njia ya uendeshaji:
INTRAMUSCULAR
Vitengo katika mfuko:
1 ML
Dawa ya aina:
Schedule D
Eneo la matibabu:
GLYCOGENOLYTIC AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0142861001; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2023-12-18
Tabia za bidhaa
GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................
Soma hati kamili
